Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas announced that the U.S. Food and Drug Administration has accepted the company’s new drug application for vepdegestrant, seeking treatment of patients with estrogen receptor positive (ER+)/HER2-negative disease whose tumors carry ESR1 mutations and who previously received endocrine-based therapy. The filing includes a company press release as Exhibit 99.1.
The FDA has assigned a Prescription Drug User Fee Act action date of June 5, 2026, establishing the target date for the agency’s decision on the application.
Arvinas Director Receives Equity Compensation Package
Director Laurie Smaldone Alsup received significant equity awards from Arvinas (NASDAQ: ARVN) on June 25, 2025. The compensation package includes:
- 16,025 Restricted Stock Units (RSUs) with zero acquisition cost
- 23,105 Stock Options with an exercise price of $7.80 per share and expiration date of June 24, 2035
Both equity awards will vest in full on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on continued service. Following these transactions, Smaldone Alsup directly owns 26,045 shares of common stock and 23,105 stock options. This grant appears to be part of the company's regular director compensation program.
Arvinas Director Briggs Morrison received significant equity compensation on June 25, 2025, consisting of two components:
- 16,025 Restricted Stock Units (RSUs) granted at $0, increasing total direct common stock ownership to 46,021 shares
- 23,105 Stock Options with exercise price of $7.80, expiring June 24, 2035
Both equity awards vest in full on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on continued service. The RSUs represent rights to receive common stock upon settlement without additional payment. The transaction was reported via Form 4 filing signed by attorney-in-fact Jared Freedberg on June 27, 2025.
Director John D. Young of Arvinas reported significant equity compensation grants on June 25, 2025, consisting of two main components:
- 16,025 Restricted Stock Units (RSUs) granted at $0, increasing his direct common stock ownership to 26,045 shares
- 23,105 Stock Options with an exercise price of $7.80 per share, expiring June 24, 2035
Both the RSUs and stock options are subject to vesting conditions, with full vesting occurring on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting. The grants are contingent on Young's continued service with Arvinas. The Form 4 was filed through his attorney-in-fact, Jared Freedberg, on June 27, 2025.
Director Linda Bain of Arvinas received significant equity compensation on June 25, 2025, consisting of two components:
- 16,025 Restricted Stock Units (RSUs) granted at $0, increasing her direct common stock ownership to 26,045 shares
- 23,105 Stock Options with an exercise price of $7.80 per share, expiring June 24, 2035
Both the RSUs and stock options will vest in full on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on continued service. This equity grant appears to be part of the company's director compensation program, aligning the director's interests with shareholders through a combination of full-value shares and performance incentives.